Cat. No. |
Product Name |
Information |
PC-42430 |
CHIR-99021 trihydrochloride
GSK-3 inhibitor
|
CHIR-99021 (Laduviglusib) trihydrochloride is a potent, specific GSK-3 inhibitor with IC50 of 5 nM and 10 nM for GSK3β and GSK3α, respectively. |
PC-42429 |
CHIR-99021 monohydrochloride
GSK-3 inhibitor
|
CHIR-99021 (Laduviglusib) monohydrochloride is a potent, specific GSK-3 inhibitor with IC50 of 5 nM and 10 nM for GSK3β and GSK3α, respectively. |
PC-42428 |
CHIR-99021
GSK-3 inhibitor
|
Laduviglusib (CHIR-99021, CT99021) is a potent, specific GSK-3 inhibitor with IC50 of 5 nM and 10 nM for GSK3β and GSK3α, respectively. |
PC-42628 |
AR-A014418
GSK-3β inhibitor
|
AR-A014418 is a potent, specific ATP-competitive inhibitor of GSK-3β with Ki/IC50 of 38/104 nM. |
PC-42787 |
TDZD-8
GSK3β inhibitor
|
TDZD-8 (GSK-3β Inhibitor I, NP 01139) is a potent, selective, non-ATP competitive GSK-3β inhibitor with IC50 of 2 uM. |
PC-45724 |
Indirubin-3-monoxime
GSK3β inhibitor
|
Indirubin-3'-monoxime is a potent GSK3β inhibitor with IC50 of 22 nM, prevents tau phosphorylation both in vitro and in vivo. |
PC-42083 |
CP21R7
GSK3β inhibitor
|
CP21R7 is a high-affinity, selective GSK3β inhibitor with IC50 of 1.8 nM, activates canonical Wnt signaling. |
PC-42674 |
TWS119
GSK3β inhibitor
|
TWS119 is a potent GSK-3β inhibitor with IC50 of 30 nM in a cell-free assay. |
PC-42664 |
BIO
GSK-3 inhibitor
|
BIO (6BIO, GSK-3 Inhibitor IX, MLS 2052) is a cell-permeable derivative of 6-bromoindirubin that displays selective inhibition of GSK-3 with IC50 of 5 nM. |
PC-22892 |
BRD0320
GSK3α/β inhibitor
|
BRD0320 is a potent, dual inhibitor of GSK3α/β with Kd of 1.2/1.9 uM respectively. |
PC-22738 |
Iodobikinin
GSK3-like kinase BIN2 inhibitor
|
Iodobikinin is a plant GSK-3/Shaggy-like kinases inhibitor that activates brassinosteroid (BR) signaling downstream of the BR receptor, binds and inhibits GSK3-like kinase BIN2. |
PC-22537 |
GSK3β inhibitor MJ34
GSK3β inhibitor
|
GSK3β inhibitor MJ34 (ISO-1479) is a potent, GSK3β selective inhibitor with IC50 of 15.4 nM, significantly reduces growth and survival of human mutant KRas dependent pancreatic tumors. |